Novartis

Novartis Foundation and Fiocruz Convene Global Experts on Strategies for Leprosy Detection

Today in Rio de Janeiro, Brazil, researchers, policy makers and public partners with a shared interest in determining strategies to detect leprosy and stop its global transmission come together
Press Release

May 30, 2017 /3BL Media/ - On May 30, 2017 together with the Oswaldo Cruz Foundation (Fiocruz), a premier research institution in Brazil focused on public health, the Novartis Foundation is co-hosting an expert meeting entitled ‘Strategies to detect and interrupt the global transmission of leprosy’ in Rio de Janeiro, Brazil.

Report Calls for Better Measurement of Access-to-Medicine Programs to Support the World’s Poorest

Pharmaceutical companies have long experience in measuring the impact of their business programs. The same should apply to their access-to-medicine efforts
Article

Richard Laing, from the Boston University (BU) School of Public Health and former World Health Organization official, says that many efforts to expand access to medicines fail to gather sufficient evidence on how effective they are. His team at BU recently issued a study highlighting these gaps, and emphasizing the need for companies to better document the impact of their programs.

Better Hearts Better Cities: Launching a Multisector Effort to Combat Hypertension in Low-income Urban Communities

Making our cities into places of wellbeing, exciting growth and opportunity will require every sector to join forces on urban health, says Dr. Ann Aerts, Head of the Novartis Foundation.
Blog

By Dr. Ann Aerts, Head of the Novartis Foundation

Walking through the wealthier streets of cities like Geneva, London or New York, it seems that health and fitness is an international obsession. National food chains boast of fresh ingredients, light options, and low-fat meals. Shelves are stacked with the trendiest superfoods – quinoa, chia seeds, kale and avocado.

Novartis Foundation and Partners Launch Initiative to Tackle Hypertension and Its Root Causes in Low-Income Urban Communities

Better Hearts Better Cities is an initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension
Press Release
  • Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension.
  • Non-communicable diseases (NCDs), including cardiovascular disease, are a growing health crisis with 75% of NCD deaths occurring in low- and middle-income countries; this is compounded by rapid urbanization.
  • The innovative approach is being tested on three continents: in Mongolia, Senegal, and Brazil.

Novartis Access and Government of Pakistan Sign Memorandum of Understanding

Novartis reaches agreement with Pakistan to supply medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
Press Release

May 12, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of National Health Services, Regulation and Coordination of the Islamic Republic of Pakistan have signed a Memorandum of Understanding to implement Novartis Access in Pakistan. Novartis Access medicines will be made available to the poorest population through hospitals under the Prime Minister’s National Health Insurance Program.

The Key to Fighting Chronic Disease in South-East Asia: Young People

More than half the ASEAN region’s 630 million people are under age 30. Harald Nusser, Head of Novartis Social Business, says that to fight the rise of chronic disease in South East Asia we need to inform its youth on the importance of healthy lifestyles.
Article

How Smart Partnerships Can Help Us Fight Chronic Diseases in Africa

As WEF Africa gets underway, Harald Nusser, Head of Novartis Social Business, emphasizes how novel solutions between the public and the private sector are needed to effectively fight the rising epidemic of chronic diseases in Africa
Blog

We all agree we need partnerships between the public and the private sector to meet the Sustainable Development Goals. Public-private partnerships (PPPs) require a better understanding between partners and innovation around institutional structures to ensure accountability, risk and benefit sharing, and value for money. These are fine words but, as the representative of a large, research-based multinational, I have found that things are not always that simple... 

Partnering to Counter the Threat of Drug-resistant Malaria

On World Malaria Day, new partnerships show what’s possible; by David Reddy, CEO of the Medicines for Malaria Venture and Harald Nusser, Head of Novartis Social Business
Article

Today is World Malaria Day, when the world’s attention turns to a mosquito-borne disease that infects millions of people in Africa, Asia-Pacific and Latin America each year.

Watch: Together We Can End Malaria for Good - New Videos from Novartis Mark World Malaria Day

The fight against malaria continues to advance, led by the hard work of countless people. On World Malaria Day, meet some of the faces behind the Novartis Malaria Initiative and listen to their stories.
Article

Novartis is proud of the passion of our people and their dedication to the fight against malaria.

Meet some of the faces behind the Novartis Malaria Initiative and listen to their stories in our new series of videos:

Watch the full video - Together we can end malaria for good

View indivdual stories:

The Specter of Malaria That Resists Treatment, New Photo Essay from Novartis

The fight against malaria continues to advance, led by the hard work of countless people in their communities. On World Malaria Day, a new photo essay from Novartis presents a collection of scenes on the ground.
Article

The fight against malaria continues to advance in Southeast Asia and Sub-Saharan Africa, led by the hard work of countless people like Agnes Akoth and Dismus Mwalukwanda, who head out every day to their communities with a firm belief that they can make a difference.

Pages

Subscribe to Novartis